Morgan Stanley launched a $250 million intellectual property securitization for Vertex Pharmaceuticals — a U.S. biotech company — where investors would be repaid from contractual milestone payments on a drug still in development, according to published reports.

This is the 18th drug-based deal for Morgan Stanley since 2004, including 5 deals managed in 2008 before the Lehman Brothers’ collapse.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.